Detail page

Knowledge Web

Person

Christoph Springfeld (1972-)

Arzt

Name	Christoph Springfeld
Time	1972- (Date of birth and death)
Place	Deutschland
Gender	männlich
Academic degree	Prof. Dr. Dr. med.
Profession	Arzt (characteristic profession)
Variant	Christoph Springfield (falsche Schreibweise)
Related	Universitätsklinikum Heidelberg. Zentrum für Innere Medizin (01/2006-) Universität Heidelberg. Medizinische Fakultät (Lehrbeauftragter) (12/2018-) Nationales Centrum für Tumorerkrankungen (2011-)
Record type	Person
GND-Identifier	123388910
Record ID	123388910
Involved in show all Durvalumab Plus Gemcitabine and Cisplatin in Patients with Advanced Biliary Tract Cancer: An Exploratory Analysis of Real-World Data Personalized treatment in localized pancreatic cancer Persister cell phenotypes contribute to poor patient outcomes after neoadjuvant chemotherapy in PDAC Cytokine release syndrome-like serum responses after COVID-19 vaccination are frequent and clinically inapparent under cancer immunotherapy Clinical effects and safety of different transarterial chemoembolization methods for bridging and palliative treatments in hepatocellular carcinoma Statin use is associated with the reduction in hepatocellular carcinoma recurrence after liver surgery Co-expression of YAP and TAZ associates with chromosomal instability in human cholangiocarcinoma Treatment stage migration and treatment sequences in patients with hepatocellular carcinoma: drawbacks and opportunities Improving radiologic communication in oncology: a single-centre experience with structured reporting for cancer patients Applicability of scoring systems predicting outcome of transarterial chemoembolization for hepatocellular carcinoma Cetuximab in Pancreatic Cancer Therapy: A Systematic Review and Meta-Analysis HER2 gene (ERBB2) amplification is a low-frequency driver with potential predictive value in gallbladder carcinoma HER2 gene (ERBB2) amplification is a rare event in non-liver-fluke associated cholangiocarcinogenesis Impact of interventions and tumor stage on health-related quality of life in patients with hepatocellular carcinoma Low frequency of mismatch repair deficiency in gallbladder cancer Prognostic Impact of Carboxylesterase 2 in Cholangiocarcinoma Programmed cell death ligand 1 (PD-L1, CD274) in cholangiocarcinoma – correlation with clinicopathological data and comparison of antibodies Mismatch repair deficiency is a rare but putative therapeutically relevant finding in non-liver fluke associated cholangiocarcinoma Imaging features of fibrolamellar hepatocellular carcinoma in gadoxetic acid-enhanced MRI Survival of Hepatocellular Carcinoma Patients Treated with Sorafenib beyond Progression Palliative chemotherapy for pancreatic adenocarcinoma: a retrospective cohort analysis of efficacy and toxicity of the FOLFIRINOX regimen focusing on the older patient A non-controlled, single arm, open label, phase II study of intravenous and intratumoral administration of ParvOryx in patients with metastatic, inoperable pancreatic cancer: ParvOryx02 protocol Influence of Different Neoadjuvant Chemotherapy Regimens on Response, Prognosis, and Complication Rate in Patients with Esophagogastric Adenocarcinoma Patients with Advanced Pancreatic Cancer and Hyperbilirubinaemia: Review and German Expert Opinion on Treatment with nab-Paclitaxel plus Gemcitabine Adjuvant radiotherapy and chemoradiation with gemcitabine after R1 resection in patients with pancreatic adenocarcinoma A retrospective comparative exploratory study on two Methylentetrahydrofolate Reductase (MTHFR) polymorphisms in esophagogastric cancer: the A1298C MTHFR polymorphism is an independent prognostic factor only in neoadjuvantly treated gastric cancer patients Successful Treatment with Nab-Paclitaxel and Gemcitabine after FOLFIRINOX Failure in a Patient with Metastasized Pancreatic Adenocarcinoma Identifizierung und Charakterisierung des Tupaia-Herpesvirus-DNA-Polymerase-Gens

Please note

The beta version does not yet contain all functions and information of the DNB portal catalogue. If you are missing information or want to order a medium, please visit the page in the DNB portal catalogue via the following link:

Katalog der Deutschen Nationalbibliothek

Christoph Springfeld (1972-)

Durvalumab Plus Gemcitabine and Cisplatin in Patients with Advanced Biliary Tract Cancer: An Exploratory Analysis of Real-World Data

Personalized treatment in localized pancreatic cancer

Persister cell phenotypes contribute to poor patient outcomes after neoadjuvant chemotherapy in PDAC

Cytokine release syndrome-like serum responses after COVID-19 vaccination are frequent and clinically inapparent under cancer immunotherapy

Clinical effects and safety of different transarterial chemoembolization methods for bridging and palliative treatments in hepatocellular carcinoma

Statin use is associated with the reduction in hepatocellular carcinoma recurrence after liver surgery

Co-expression of YAP and TAZ associates with chromosomal instability in human cholangiocarcinoma

Treatment stage migration and treatment sequences in patients with hepatocellular carcinoma: drawbacks and opportunities

Improving radiologic communication in oncology: a single-centre experience with structured reporting for cancer patients

Applicability of scoring systems predicting outcome of transarterial chemoembolization for hepatocellular carcinoma

Cetuximab in Pancreatic Cancer Therapy: A Systematic Review and Meta-Analysis

HER2 gene (ERBB2) amplification is a low-frequency driver with potential predictive value in gallbladder carcinoma

HER2 gene (ERBB2) amplification is a rare event in non-liver-fluke associated cholangiocarcinogenesis

Impact of interventions and tumor stage on health-related quality of life in patients with hepatocellular carcinoma

Low frequency of mismatch repair deficiency in gallbladder cancer

Prognostic Impact of Carboxylesterase 2 in Cholangiocarcinoma

Programmed cell death ligand 1 (PD-L1, CD274) in cholangiocarcinoma – correlation with clinicopathological data and comparison of antibodies

Mismatch repair deficiency is a rare but putative therapeutically relevant finding in non-liver fluke associated cholangiocarcinoma

Imaging features of fibrolamellar hepatocellular carcinoma in gadoxetic acid-enhanced MRI

Survival of Hepatocellular Carcinoma Patients Treated with Sorafenib beyond Progression

Palliative chemotherapy for pancreatic adenocarcinoma: a retrospective cohort analysis of efficacy and toxicity of the FOLFIRINOX regimen focusing on the older patient

A non-controlled, single arm, open label, phase II study of intravenous and intratumoral administration of ParvOryx in patients with metastatic, inoperable pancreatic cancer: ParvOryx02 protocol

Influence of Different Neoadjuvant Chemotherapy Regimens on Response, Prognosis, and Complication Rate in Patients with Esophagogastric Adenocarcinoma

Patients with Advanced Pancreatic Cancer and Hyperbilirubinaemia: Review and German Expert Opinion on Treatment with nab-Paclitaxel plus Gemcitabine

Adjuvant radiotherapy and chemoradiation with gemcitabine after R1 resection in patients with pancreatic adenocarcinoma

A retrospective comparative exploratory study on two Methylentetrahydrofolate Reductase (MTHFR) polymorphisms in esophagogastric cancer: the A1298C MTHFR polymorphism is an independent prognostic factor only in neoadjuvantly treated gastric cancer patients

Successful Treatment with Nab-Paclitaxel and Gemcitabine after FOLFIRINOX Failure in a Patient with Metastasized Pancreatic Adenocarcinoma

Identifizierung und Charakterisierung des Tupaia-Herpesvirus-DNA-Polymerase-Gens